Refine
Has Fulltext
- yes (323)
Is part of the Bibliography
- yes (323)
Year of publication
Document Type
- Journal article (191)
- Doctoral Thesis (131)
- Review (1)
Keywords
- NFATc1 (15)
- apoptosis (14)
- NFAT (10)
- immunohistochemistry (10)
- lymphoma (10)
- Transkriptionsfaktor (9)
- Apoptose (8)
- B-Zell-Lymphom (8)
- CXCR4 (8)
- DLBCL (8)
- Non-Hodgkin-Lymphom (8)
- T-Lymphozyt (7)
- cancer (7)
- prognosis (7)
- Apoptosis (6)
- Lymphom (6)
- T cells (6)
- breast cancer (6)
- gene expression (6)
- glioblastoma (6)
- multiple myeloma (6)
- thymoma (6)
- thymus (6)
- B cells (5)
- Lymphome (5)
- Proliferation (5)
- astrocytoma (5)
- follicular lymphoma (5)
- glioblastoma multiforme (5)
- recurrence (5)
- therapy (5)
- Amplifikation (4)
- Autoaggressionskrankheit (4)
- EGFR (4)
- FISH (4)
- Fluoreszenz-in-situ-Hybridisierung (4)
- Follikuläres Lymphom (4)
- Immunhistochemie (4)
- Immuntherapie (4)
- Krebs <Medizin> (4)
- Microarray (4)
- NF-AT (4)
- Prognose (4)
- Thymom (4)
- Thymus (4)
- amplification (4)
- brain (4)
- chemokine receptor (4)
- expression (4)
- forensic neuropathology (4)
- gene regulation (4)
- mRNA (4)
- machine learning (4)
- metastasis (4)
- relapse (4)
- thymic carcinoma (4)
- transcription factors (4)
- B-Lymphozyten (3)
- Brustkrebs (3)
- CGH (3)
- EBV (3)
- Ependymom (3)
- Genexpression (3)
- Histopathologie (3)
- Hodgkin lymphoma (3)
- Immunglobulin M (3)
- Keimzentrum (3)
- Lymphknoten (3)
- Lymphoma (3)
- Lymphozyten (3)
- MALT1 (3)
- MYC (3)
- Malignes Lymphom (3)
- Medizin (3)
- Myasthenia gravis (3)
- NRF2 (3)
- PET/CT (3)
- Pathologie (3)
- T-cell lymphoma (3)
- adrenocortical carcinoma (3)
- biomarker (3)
- brain tumor (3)
- cerebrospinal fluid (3)
- comparative genomic hybridization (3)
- diffuse large B-cell lymphoma (3)
- flow cytometry (3)
- forensic neurotraumatology (3)
- germinal center (3)
- glioma (3)
- loss of heterozygosity (3)
- melanoma (3)
- monoclonal antibody (3)
- myasthenia gravis (3)
- neuronal differentiation (3)
- poor prognosis (3)
- positron emission tomography (3)
- protein (3)
- surgical oncology (3)
- AICD (2)
- ATF4 (2)
- Angeborene Immunität (2)
- Antigen (2)
- Antikörper (2)
- B-cell lymphoma (2)
- BCL6 (2)
- CD30 (2)
- CRISPR/Cas9 (2)
- CXCR2 (2)
- Colonkrebs (2)
- Cushing’s syndrome (2)
- Deletion (2)
- Differenzierung (2)
- E-cadherin (2)
- EMT (2)
- Epidermaler Wachstumsfaktor-Rezeptor (2)
- Epstein-Barr-Virus (2)
- Expression (2)
- FFPE (2)
- FGFR (2)
- Glioblastoma (2)
- Graft-versus-leukemia (2)
- HNSCC (2)
- Hodgkin (2)
- Humorale Immunität (2)
- Immuncytochemie (2)
- Immunglobuline (2)
- Immunologie (2)
- Immunotherapy (2)
- Immunsystem (2)
- KEAP1 (2)
- Krebs (2)
- LOH (2)
- Lymphogranulomatose (2)
- MALT (2)
- MALT-Lymphom (2)
- MALT-lymphoma (2)
- MPS1 (2)
- Magenkarzinom (2)
- Magenkrebs (2)
- Mammakarzinom (2)
- Mantelzell-Lymphom (2)
- Mantle cell lymphoma (2)
- Maus (2)
- Methylation (2)
- Methylierung (2)
- Mikrosatellitenanalyse (2)
- Mikrosatelliteninstabilität (2)
- Molekularbiologie (2)
- Monoklonaler Antikörper (2)
- Multiple Myeloma (2)
- NAFLD (2)
- NASH (2)
- NHL (2)
- NSCLC (2)
- Nekrose (2)
- Neuroinflammation (2)
- Nfatc1 (2)
- Onkogen (2)
- PD-L1 (2)
- PET (2)
- PTCL (2)
- Plattenepithelcarcinom (2)
- Protein p53 (2)
- Rhabdomyosarcoma (2)
- SC-1 (2)
- Signaltransduktion (2)
- Speicheldrüse (2)
- T-Lymphozyten (2)
- T-Zell-Lymphome (2)
- T-Zellen (2)
- T-cell differentiation (2)
- TAF15 (2)
- TTK (2)
- Thymuskarzinome (2)
- Transkriptionsfaktoren (2)
- Tumor (2)
- Tumorimmunologie (2)
- Tumorsuppressorgen (2)
- USP28 (2)
- VEGF (2)
- alloreactive T cells (2)
- amplicon sequencing (2)
- angiogenesis (2)
- animal model (2)
- antigen (2)
- autoimmune disease (2)
- cancer stem cells (2)
- cancers and neoplasms (2)
- carcinomas (2)
- case report (2)
- cell staining (2)
- cell-cycle arrest (2)
- chemokine (2)
- chromosomal aberration (2)
- classification (2)
- cytotoxic T cells (2)
- development (2)
- discriminant analysis (2)
- endothelial cells (2)
- enzyme-linked immunoassays (2)
- ependymoma (2)
- extranodal (2)
- gastric carcinoma (2)
- gene (2)
- genetic aberrations (2)
- genetische Aberrationen (2)
- grade 3B (2)
- humoral immunity (2)
- imaging (2)
- immune response (2)
- immunohistochemistry techniques (2)
- immunotherapy (2)
- in vivo imaging (2)
- inflammation (2)
- innate immunity (2)
- keratinocytes (2)
- kidneys (2)
- low-grade glioma (2)
- lung cancer (2)
- malignant tumors (2)
- mantle cell lymphoma (2)
- messenger RNA (2)
- miRNA (2)
- mice (2)
- microenvironment (2)
- microsatellite instability (2)
- mitochondrial DNA (2)
- molecular diagnostics (2)
- molecular imaging (2)
- mouse models (2)
- mutation (2)
- mutations (2)
- natural immunity (2)
- natürliche Antikörper (2)
- natürliche Immunität (2)
- neuroinflammation (2)
- obesity (2)
- organoids (2)
- oxidative stress (2)
- p53 (2)
- pancreatic cancer (2)
- plasma cells (2)
- positron emission tomography/computed tomography (2)
- postnatal development (2)
- principal component analysis (2)
- proteomics (2)
- radiotherapy (2)
- rat (2)
- receptor tyrosine kinases (2)
- regression analysis (2)
- regulatory T cells (2)
- senile lymphoproliferation (2)
- signal transduction (2)
- survival (2)
- targeted therapy (2)
- temozolomide (2)
- transcription (2)
- translocation (2)
- tumor immunology (2)
- tumor microenvironment (2)
- tumor suppressor gene (2)
- vestibular schwannoma (2)
- vitamin D (2)
- - (1)
- 16S-rRNA (1)
- 3D ex vivo models (1)
- 3D lung tumor tissue models (1)
- <sup>18</sup>F-FDG (1)
- <sup>68</sup>Ga-Pentixafor (1)
- AD-AID (1)
- ADAM9 (1)
- ADP-ribosylation toxins (1)
- AICDA (1)
- AID-ΔE4a (1)
- AIDS (1)
- AIRE (1)
- AKT-signaling (1)
- ALCL (1)
- ALK-1 (1)
- AMACR (1)
- AOM/DSS (1)
- APECED (1)
- ATF5 (1)
- ATG7 (1)
- ATM (1)
- Aberrationen (1)
- Activation (1)
- Activation induced cell death/AICD (1)
- Adamantiades-Behçet disease (1)
- Adult (1)
- Akute Ösophagusnekrose (1)
- Allogenic hematopoietic stem cell transplantation (1)
- Alpha therapy (1)
- Alter (1)
- Alzheimerkrankheit (1)
- Amplicon Sequencing (1)
- Anergy (1)
- Aneuploidie (1)
- Antibodies (1)
- Antigen CD30 (1)
- Antigen CD8 (1)
- Antiparanodal Autoantibodies (1)
- Aphthae (1)
- Apoptose-Resistenz (1)
- Apoptoseinduktion (1)
- Appendizitis (1)
- Autoantikörper (1)
- Autoimmune diseases (1)
- Autoimmunerkrankung (1)
- Autoimmungastritis (1)
- Autoimmunkrankheit (1)
- Autoimmunregulator (1)
- Autoregulation (1)
- B Lymphocytes (1)
- B cell lymphoma (1)
- B cell malignancies (1)
- B lymphocytes (1)
- B-Lymphozyt (1)
- B-Lymphozyt-Tumor (1)
- B-MYB (1)
- B-Zell Lymphome (1)
- B-Zell-Leukämie (1)
- B-Zell-Rezeptor (1)
- B-Zellen Differenzierung (1)
- B-cell Lymphome (1)
- B-cell differentiation (1)
- B-cells (1)
- B-lymphocytes (1)
- BAC-Konstrukt (1)
- BAC-construct (1)
- BARB-4 (1)
- BCL1 rearrangement (1)
- BCL1-Rearrangement (1)
- BCL2 (1)
- BIRC7 (1)
- BLIMP1 (1)
- BRMS1 (1)
- Barrett-Ösophagus (1)
- Bauchfellentzündung (1)
- Bauchspeicheldrüsenkrebs (1)
- Bcl-2-Gen (1)
- Bcl-2-gene (1)
- Behçet’s disease (1)
- Bevacizumab (1)
- Bioluminescence imaging (1)
- Biomarker (1)
- Bisphosphonate (1)
- Blasenkrebs (1)
- Blimp-1 (1)
- Blimp1 (1)
- Blinddarmentzündung (1)
- Bone chips (1)
- Bone marrow cells (1)
- Bone marrow transplantantation (1)
- Bone marrow transplantation (1)
- Braak (1)
- Breast-cancer (1)
- Bruton Tyrosine Kinase (1)
- Burkitt (1)
- B‐cell lymphoma (1)
- C-Myc (1)
- C/EBP (1)
- C/EBP-Beta (1)
- C/EBPβ (1)
- C3 (1)
- CABG-operation (1)
- CBP (1)
- CCR7 (1)
- CD 27 (1)
- CD-Marker (1)
- CD/metabolism (1)
- CD117 (1)
- CD133 (1)
- CD27 (1)
- CD274 (1)
- CD30-Rezeptor (1)
- CD319 (1)
- CD4+ (1)
- CD40 ligand (1)
- CD5-positive B-Lymphozyten (1)
- CD56 (1)
- CD8 (1)
- CD9 (1)
- CFR-1 (1)
- CHAC1 (1)
- CIITA (1)
- CK5 (1)
- COVID-19 (1)
- CRC (1)
- CRISPR-Cas9 (1)
- CRISPR/Cas-Methode (1)
- CS1 (1)
- CSF (1)
- CTL function (1)
- CTNNB1 (1)
- CX5461 (1)
- CXCL5 (1)
- CXCL8 (1)
- CXCR1 (1)
- CXCR4/SDF-1 (1)
- CXCR5 (1)
- CXCR7 (1)
- CYP24A1 (1)
- CYP2W1 (1)
- Calcineurin (1)
- Calcium (1)
- Cancer (1)
- Cancer genetics (1)
- Cancer treatment (1)
- Cancer/Testis Antigene (1)
- Cancer/Testis antigen (1)
- Candida (1)
- Carcinogenese (1)
- Cartilage Oligomeric Matrix Protein (1)
- Caspase 12 (1)
- Ccl2 (1)
- Chains (1)
- Checkpoint-Inhibitor (1)
- Chemokin (1)
- Chemokin CXCL10 (1)
- Chemokine (1)
- Chemokinrezeptor (1)
- Chemotherapy (1)
- Childhood (1)
- Chromosom 9 (1)
- Chromosome 18 (1)
- Chromosomenaberration (1)
- Cisplatin (1)
- Clonality (1)
- Clonality analysis (1)
- Cocktail (1)
- Cushings syndrome (1)
- Cushing’s disease (1)
- Cytogenetik (1)
- Cytotoxizität (1)
- DCIS (1)
- DCR1 (1)
- DEL(5Q) (1)
- DHAP (1)
- DLBCL multilobated (1)
- DLBCL multilobuliert (1)
- DLBL (1)
- DNA hypermethylation (1)
- DNA methylation (1)
- DNA-PK (1)
- DNS-Reparatur (1)
- DOTATOC (1)
- DT40 cells (1)
- DWI (1)
- Defined burkitts lymphoma (1)
- Delta Repertoire (1)
- Dendritic cells (1)
- Dendritische Zelle (1)
- Design (1)
- Diabetes mellitus (1)
- Diagnostik (1)
- Dickdarmkrebs (1)
- Differentielle Genexpression (1)
- Diffuse großzellige B-Zell Lymphome (1)
- Diffuses großzelliges B-Zell Lymphom (1)
- Diphosphonate (1)
- Durchflusszytometrie (1)
- E-Learning (1)
- EAHP/SH bone marrow workshop (1)
- EATCL (1)
- EBER in situ hybridization (1)
- EGF (1)
- EL-4 (1)
- EL-4 Zellen (1)
- ERM proteins (1)
- ETL (1)
- EZH1 (1)
- EZH2 (1)
- Endothel (1)
- Enteropathie-Typ (1)
- Entzündung (1)
- Enzephalitis (1)
- Epidemiological study (1)
- Epigenese (1)
- Epigenetics (1)
- Epigenetik (1)
- Epitope (1)
- Epstein-Ba (1)
- Epstein-Barr virus (1)
- Ewing-Sarkom (1)
- Extrafollikuläre Aktivierung (1)
- Extraocular eye muscles (1)
- F-19 MRI (1)
- FADD (1)
- FARS1 (1)
- FDG PET/CT (1)
- FGF-pathway (1)
- FINCA (1)
- FL (1)
- FL3B (1)
- FLT-PET (1)
- FTIR spectroscopy (1)
- Factor receptor (1)
- Fas (1)
- Fibrin glue (1)
- Fluoreszenzaktivierter Zellsortierer (1)
- Forskolin (1)
- Frequency (1)
- Frühdiagnostik (1)
- Frühphase (1)
- GABP (1)
- GATA-3 (1)
- GFAP (1)
- GIST (1)
- GLP-1 (1)
- GRP78 (1)
- GSH (1)
- Gallium (1)
- Gen-Anordnung (1)
- Genamplifikation (1)
- Gene (1)
- Gene-expression (1)
- Genetik (1)
- Genitoanal region (1)
- Genome wide analysis (1)
- Genregulation (1)
- Gewebemicroarray (1)
- Gewebeverlust (1)
- Glioma stem cells (1)
- Glykosylierung (1)
- Grad 3B (1)
- Grading (1)
- Graft-versus-host-disease (1)
- GvHD (1)
- GvL (1)
- Gvhd (1)
- H. pylori Gastritis (1)
- H.pylori gastritis (1)
- H2O2 (1)
- H3K27me3 (1)
- HD (1)
- HER2 conversion (1)
- HER2 targeted therapy (1)
- HER2-low (1)
- HHV8 (1)
- HNSC (1)
- HPK1 (1)
- HSC (1)
- Hals-Nasen-Ohren-Heilkunde (1)
- Hals-Nasen-Ohren-Tumor (1)
- Hans algorithm (1)
- Harnblasenkarzinom (1)
- Hautlymphom (1)
- Head (1)
- Head and neck cancers (1)
- Heavy chain mutations (1)
- Helicobacter (1)
- Helicobacter pylori (1)
- Helicobacter-pylori-Infektion (1)
- High-resolution (1)
- Hirntumor (1)
- Histologie (1)
- Histone deacetylase inhibition (1)
- Histopathology (1)
- Hitzeschockprotein (1)
- Hodgkin-Lymphom (1)
- Hodgkin´s disease (1)
- Hsp90 (1)
- Human antibodies (1)
- Humane Antikörper (1)
- Hybridom (1)
- Hypercortisolism (1)
- Hypermutation (1)
- Hypopharynxkarzinom (1)
- IDH (1)
- IDH1/2 (1)
- IFN (1)
- IFN-γ (1)
- IGF1R (1)
- IGF2BP3 (1)
- IL-10 (1)
- IL-17 (1)
- IL-2 (1)
- IL-4 (1)
- IL-5 (1)
- IL2 (1)
- IMP3 (1)
- IR (1)
- IRF4 (1)
- Ibrutinib (1)
- IgG4 (1)
- IgM (1)
- IgM isotyp (1)
- Images (1)
- Immun-Checkpoint (1)
- Immunbiologie (1)
- Immunfluoreszenz (1)
- Immunhistologie (1)
- Immunisierung (1)
- Immunität <Medizin> (1)
- Immunmodulation (1)
- Immunology (1)
- Immunoreceptors (1)
- Immunosuppression (1)
- Immunphänotyp (1)
- Immunreaktion (1)
- Immunrezeptoren (1)
- In-vivo (1)
- Inflammation (1)
- Intestinal Intraepithelial Lymphocy (1)
- Intrakranielle Blutung (1)
- Involution (1)
- Iron-oxide (1)
- Irradiation (1)
- Isoformen (1)
- JAK inhibitor (1)
- JNK (1)
- JUN (1)
- KIT (1)
- KRAS (1)
- KRAS biomarker signatures (1)
- Kaposi sarcoma (1)
- Keimzelltumor (1)
- Keimzentrumsreaktion (1)
- Keratine (1)
- Keratinozyt (1)
- Ki-67 (1)
- KiSS1 (1)
- Kidney cancer (1)
- Kiefernekrosen (1)
- Killerzelle (1)
- Kindesalter (1)
- Klarzellsarkom (1)
- Klassifikation (1)
- Klonale Evolution (1)
- Klonalitaetsanalysen (1)
- Klonalität (1)
- Knochenmetastase (1)
- Knochensialoprotein (1)
- Knock-out-Mäuse (1)
- Kolonkarzinom (1)
- Komparative Genomische Hybridisierung (1)
- Komparative genomische Hybridisierung (1)
- Krebstherapie (1)
- Kreuzreaktion (1)
- LESA (1)
- LGA (1)
- LITAF (1)
- LM-1 (1)
- Lagerungsmedium (1)
- Laminin (1)
- Langfristige Prognose (1)
- Larynxkarzinom (1)
- Lateral suboccipital craniectomy (1)
- Lesions (1)
- Leukoplakia (1)
- Leukoplakie (1)
- Lichen planus (1)
- Lichen ruber planus (1)
- Ligand (1)
- Lipom (1)
- Liposarkom (1)
- Lipotoxizität (1)
- Lokalisation (1)
- Low grade Astrocytoma (1)
- Lung-cancer (1)
- Lymph2Cx assay (1)
- Lymphadenitis (1)
- Lymphdrüse (1)
- Lymphocytes (1)
- Lymphomas (1)
- Lymphozyt (1)
- Lymphsystem (1)
- MAGE A3 (1)
- MAGE-A (1)
- MAGE-A-Antigene (1)
- MAGE-A-antigens (1)
- MALT lymphoma (1)
- MALT-Lymphome (1)
- MALT-Typ Lymphome (1)
- MALT-type lymphoma (1)
- MALT1-Gen (1)
- MALT1-gene (1)
- MAPK (1)
- MCL (1)
- MDS (1)
- MEF2D (1)
- MEK/ERK-signaling (1)
- MGMT (1)
- MGMT promoter methylation (1)
- MHC (1)
- MITF-low (1)
- MIZ1 (1)
- MMP2 (1)
- MMP9 (1)
- MRSA (1)
- MTB (1)
- MTCH2 (1)
- MTX (1)
- Malignancies (1)
- Malt (1)
- Mantelzellen (1)
- Mantelzelllymphom (1)
- Marginal zone lymphomas (1)
- Marginalzonen-B-Zell-Lymphom (1)
- Marginalzonen-Lymphome (1)
- Masaoka (1)
- Maschinelles Lernen (1)
- Mediastinum (1)
- Medical research (1)
- Mensch (1)
- Merlin (1)
- Metastases (1)
- Mikroglia (1)
- Mikrosatelliten (1)
- Mikrosatelliten-Instabilität (1)
- Milz (1)
- Mismatch (1)
- Molecular pathogenesis (1)
- Molekulargenetik (1)
- Monoklonaler Antikrper (1)
- Morphometrie (1)
- Mukosa-assoziiertes lymphatisches Gewebe (1)
- Multigentests (1)
- Multiple Sklerose (1)
- Mundhöhlentumor (1)
- Muskelzelle (1)
- Mutation (1)
- MyD88 (1)
- Myasthenia gravi (1)
- Myb-MuvB (1)
- Myc (1)
- Myeloma cells (1)
- Myelomas (1)
- Mykose (1)
- Mysthenia Gravis (1)
- N-Glykosylierungsmotive (1)
- N-glycosylation sites (1)
- NEC (1)
- NET (1)
- NF-KAPPA-B (1)
- NF-\(\kappa\)B pathway (1)
- NF-κB (1)
- NFAT in EAE (1)
- NFATc (1)
- NFATc1 sumoylation (1)
- NFATc1/αA (1)
- NFATc3 (1)
- NFATs (1)
- NFE2L2 (1)
- NFkappaB (1)
- NGS (1)
- NHLRC2 (1)
- NIH-3T3 (1)
- NLPHL (1)
- NORM-1 (1)
- NR3C1 (1)
- NSG (1)
- NSG-SGM3 (1)
- NY-ESO 1 (1)
- Natürliche Killerzelle (1)
- Nebennierenrinde (1)
- Nebennierenrindenkrebs (1)
- Nestin (1)
- Neurodegeneration (1)
- Nicotinischer Acetylcholinrezeptor (1)
- Nierenzellcarcinom (1)
- Nodo-parandopathy (1)
- Non Hodgkin Lymphoma (1)
- Non Hodgkin Lymphome (1)
- Non-Hodgkin Lymphome (1)
- Non-Hodgkin-Lymphome (1)
- Nrf2 (1)
- Nuclear Factor of Activated T cells (NFAT) (1)
- Nuclear expression (1)
- Nur77 (1)
- OBF-1 OCA-B (1)
- OCT-1-deficient mice (1)
- Oncotype DX® (1)
- OncotypeDX (1)
- OncotypeDX\(^{®}\) (1)
- Oral Precancer (1)
- Oral mucosa (1)
- Oral squamous cell carcinoma (1)
- Organoids (1)
- Osteoarthrose (1)
- Osteogeneration (1)
- Osteopontin (1)
- PAI-1 (1)
- PAM-1 (1)
- PAT-LM1 (1)
- PAT-SM6 (1)
- PCDHGC3 (1)
- PCI-32765 (1)
- PD-1 (1)
- PI3K (1)
- PKA (1)
- PLAG1 rearrangement (1)
- POLKADOTS (1)
- PRDI-BF1 (1)
- PRRT (1)
- PTCL NOS (1)
- PTEN (1)
- Paraffin (1)
- Parkinson (1)
- Parkinsons disease (1)
- Parkinson’s disease (1)
- Particles (1)
- Pathohistologie (1)
- Pathway (1)
- Pentixafor (1)
- Phylogenetik (1)
- Phänotyp (1)
- Plaques und Tangels (1)
- Plasmozytom (1)
- Plattenepithelkarzinom (1)
- Polyadenylierung (1)
- Polymerase-Kettenreaktion (1)
- Positron emission tomography (1)
- Positronen-Emissions-Tomografie (1)
- Posttranskriptionelle Regulation (1)
- Pou2af1 (1)
- Primär kutane Marginalzonen-Lymphome (1)
- Primär kutanes Lymphom (1)
- Profiling (1)
- Prog (1)
- Prognosis (1)
- Proliferation index (1)
- Proliferationsindex (1)
- Promoter (1)
- Promotor (1)
- Promotor <Genetik> (1)
- Prophylaxe (1)
- Prostata-DNA-Datenbank (1)
- Prostatakarzinom (1)
- Protein-DNA-Interaktion (1)
- Protein-Protein-Interaktion (1)
- Präkanzerose (1)
- Präkanzerosen (1)
- R-CHOP (1)
- RCC (1)
- RNA Expression (1)
- RNA probe (1)
- RNA-Sequenzierung (1)
- RNAPOL1 (1)
- RNAScope (1)
- ROS (1)
- RPS27 (1)
- RYGB (1)
- Rac (1)
- Raf (1)
- Random Forest (1)
- Rats (1)
- Receptor-Tyrosine Kinases (1)
- Regulatorgen (1)
- Regulatory-cells (1)
- Reifung (1)
- Renal cell carcinoma (1)
- Restriktionsfragmentlängenpolymorphismus (1)
- Retroperitoneum (1)
- Retroviraler Gentransfer (1)
- Rezeptor-Expression (1)
- Rezeptor-Tyrosinkinasen (1)
- Rhabdomyosarkom (1)
- Rheumatoid arthritis (1)
- Rheumatoide Arthritis (1)
- Rho-GTPases (1)
- Ribosomale RNS (1)
- Richter's syndrome (1)
- Richter-Syndrom (1)
- Risiko (1)
- Risikofaktoren (1)
- Risk factors (1)
- Rituximab plus (1)
- Riutximab (1)
- Rotatorenmanschettensyndrom (1)
- S-Phase-Fraktion (1)
- S-phase fraction (1)
- SAM-6 (1)
- SARS-CoV-2 (1)
- SB332235 (1)
- SGN-35 (1)
- SHARP-Screening (1)
- SIV (1)
- SLC7A11 (1)
- SOAT1 (1)
- SSTR (1)
- STEAP-1 (1)
- Sarkom (1)
- Schleimhaut (1)
- Schleimhaut-Ulzera (1)
- Schütteltrauma (1)
- Senile Lymphoproliferation (1)
- Sequenzdaten (1)
- Skelettmuskulatur (1)
- Soft-tissue infection (1)
- Sox9 (1)
- Speicheldrüsenkrebs (1)
- Speiseröhre (1)
- SphK1 (1)
- Spinal dissemination (1)
- Spindle cell (1)
- Spleen (1)
- Sporadic Alzheimer’s disease (1)
- Sporadische Alzheimer-Demenz (1)
- Sprue (1)
- Squamous cell carcinoma (1)
- Staging (1)
- Stammzelltransplantation (1)
- Stanzbiopsie (1)
- Staphylococcus aureus (1)
- Staphylococcus aureus immune response (1)
- Starry Sky (1)
- Sternberg-Riesenzelle (1)
- Sunitinib (1)
- Suppression (1)
- Surgery (1)
- Survival (1)
- Synovialmembran (1)
- Synovialsarkom (1)
- T Lymphocytes (1)
- T Zellen (1)
- T cell differentiation (1)
- T cell receptors (1)
- T helper cells (1)
- T lymphocyte (1)
- T(H)17 cells (1)
- T-Helfer Zellen (1)
- T-Lymphozyt info (1)
- T-Zell-Entwicklung (1)
- T-Zell-Lymphom (1)
- T-Zell-Marker (1)
- T-Zell-Reifung (1)
- T-Zell-Rezeptor (1)
- T-Zelldifferenzierung (1)
- T-cell non-Hodgkin's lymphomas (1)
- T-cell receptor (1)
- T-cell transfer (1)
- T-cells (1)
- T-follicular regulatory cell (1)
- T-lymphocytes (1)
- TAD-A (1)
- TCR signaling cascade (1)
- TGF-alpha (1)
- TP53 (1)
- TP53 mutations (1)
- T\(_{reg}\) and Foxp3 (1)
- Targeted Therapies (1)
- Targets (1)
- Telepathologie (1)
- Temozolomide (1)
- Th (1)
- Th17 (1)
- Therapie (1)
- Thomas (Arzt) (1)
- Thymocytes (1)
- Thymoma (1)
- Thymome (1)
- Thymopoese (1)
- Thymuskrankheit (1)
- Tissue-Microarray-Technik (1)
- Tlymphozyten (1)
- Tolerance (1)
- Toleranz <Biologie> (1)
- Tonsilla (1)
- Tracking (1)
- Transcription factors (1)
- Transcription-factor (1)
- Transkription <Genetik> (1)
- Transkriptionfaktoren (1)
- Transkriptionsfaktor NF-KappaB (1)
- Transkriptionsfaktor info (1)
- Translational research (1)
- Translokation (1)
- Translokation t(11;14)(q13;q32) (1)
- Translokation t(11;18) (1)
- Transplantat-Wirt-Reaktion (1)
- Transplantatabstoßung (1)
- Tregs (1)
- Trisomie (1)
- Tumor Microenvironment (1)
- Tumor Treating Fields (TTFields) (1)
- Tumor-necrosis-factor (1)
- Tumorantigen (1)
- Tumorimmunity (1)
- Tumorimmunität (1)
- Tumornephrektomie (1)
- Tumorprogression (1)
- Tumorzell-Migration (1)
- Tumour markers (1)
- Typ 1 Muskelfasern (1)
- Tyrosine kinase inhibition (1)
- UMAP (1)
- USP8 (1)
- USP9X (1)
- UV-Strahlung (1)
- Urothelkarzinom (1)
- Usage (1)
- Uveitis (1)
- VDR (1)
- VH-JgG Mutationen (1)
- Vascular endothelial Growth Factor (1)
- Venenlagerung (1)
- Verlust der Heterozygosität (1)
- Vielfalt (1)
- Virtual Microscopy (1)
- Virtuelle Mikroskopie (1)
- Vitamin-K-Mangel-Blutung (1)
- Vorhersage (1)
- WHO (1)
- WHO-Klassifikation (1)
- WNT signaling (1)
- WTAP (1)
- Waldeyer-Ring (1)
- Waldeyer´s ring (1)
- Waldeyer’s tonsillar ring (1)
- Wilms tumour (1)
- XIAP (1)
- YAP (1)
- Zellmigration (1)
- Zelltod (1)
- Zellzyklus (1)
- Zentroblastisches Lymphom (1)
- Zytokeratin (1)
- [18F]FDG-PET-CT (1)
- [18F]Fluorodeoxythymidine (1)
- [\(^{68}\)Ga] pentixafor (1)
- [\(^{68}\)Ga]Pentixafor (1)
- \(^{68}\)Ga-Pentixafor (1)
- abdominal lymph node metastases (1)
- aberrations (1)
- abnormalities (1)
- actin (1)
- actin filament (1)
- actin filaments (1)
- activation (1)
- acute esophageal necrosis (1)
- acute graft-versus host disease (1)
- acute graft-versus-host disease (1)
- acute lymphoblastic leukemia (1)
- acute lymphocytic leukaemia (1)
- acute myeloid leukaemia (1)
- acute myeloid leukemia (1)
- adenomas (1)
- adenosine kinase (1)
- adhesion (1)
- adrenal glands (1)
- adrenal tumor (1)
- adrenocortical (1)
- adrenocortical cancer (1)
- adrenocortical tissues (1)
- adrenocortical tumors (1)
- affinity (1)
- aggressive B‐cell lymphoma (1)
- allergy (1)
- allogenic stem cell transplantation (1)
- allografts (1)
- alternative splicing (1)
- aluminum granuloma (1)
- aminoacyl‐tRNA synthetases (1)
- amplifications (1)
- amyloidoma (1)
- amyloidosis (1)
- anaplasia (1)
- anaplastic large T-cell-lymphoma (1)
- anaplastic large cell lymphoma (1)
- anaplastic large cell lymphoma (ALCL) (1)
- anaplastic medulloblastoma (1)
- anaplastisch-großzellige T-Zell-Lymphome (1)
- aneuploidy (1)
- aneusomy (1)
- angeborenes Immunsystem (1)
- annecin-V (1)
- anti-CD30 drug conjugate (1)
- anti-inflammatory cytokines (1)
- antibodies (1)
- antibody (1)
- antibody-mediated (1)
- antigen loss (1)
- antigens (1)
- antikörpervermittelt (1)
- antioxidant function (1)
- aortic adventitia (1)
- aortokoronarer Venenbypass (1)
- apoptosis, Myc (1)
- appendicitis (1)
- arteriovenous loop (1)
- atopic dermatitis (1)
- atrial natriuretic peptide (1)
- aurora kinase A polymorphism (1)
- aurorakinase B (1)
- autoantibodies (1)
- autoantibody (1)
- autoantigen (1)
- autoimmune regulator (1)
- autoimmunregulator (1)
- autoimmuns gastitis (1)
- autologous transplantation (1)
- autophagy (1)
- axonally transported proteins (1)
- azacitidine (1)
- b-cell lymphoma of the MALT type (1)
- b-cell lymphomas (1)
- b-cell receptor (1)
- bacterial toxins (1)
- behavior (1)
- benige tumor (1)
- beta-catenin (1)
- binding (1)
- binding proteins (1)
- biofluid (1)
- bioinformatic clustering (1)
- biological sciences (1)
- biomarker prediction (1)
- biopsy (1)
- biosynthesis (1)
- bisphosphonate (1)
- blood–brain barrier (1)
- bone disease (1)
- bone marrow biopsy (1)
- bone marrow cells (1)
- bone marrow–spleen–liver large B‐cell lymphoma (1)
- bone metastases (1)
- bone metastasis (1)
- bone sialoprotein (1)
- boolean in silico models (1)
- botulinum C2 toxin (1)
- breast carcinoma (1)
- buparlisib (1)
- c-MYC (1)
- c-kit (1)
- c-myc (1)
- c/ebp (1)
- cAMP (1)
- cadaver multiorgan preservation (1)
- calcium (1)
- cancer care (1)
- cancer detection (1)
- cancer diagnosis (1)
- cancer metabolism (1)
- cancer of unknown primary (CUP) (1)
- cancer therapy (1)
- cancer treatment (1)
- carcinogenesis (1)
- carcinoma (1)
- carcinoma metastases to pancreas (1)
- cardiac transplantation (1)
- cardiomyocyte proliferation (1)
- cartilage oligomeric matrix protein (1)
- caspase-3 (1)
- catenin (1)
- caveolin-1 (1)
- cell binding (1)
- cell cycle and cell division (1)
- cell death (1)
- cell of origin (1)
- cells (1)
- cellular uptake (1)
- centroblastic lymphoma of the multilobated subtype (1)
- cerebellum (1)
- cerebral cortex (1)
- cerebropulmonary disease (1)
- cetuximab (1)
- checkpoint inhibition (1)
- chemokine receptor-4 (1)
- chemokinereceptor (1)
- childhood (1)
- childhood interstitial lung disease (1)
- children (1)
- children´s interstitial lung disease (chILD) lipoid pneumonia (1)
- cholesterol pneumonia (1)
- cholesterol pneumonitis (1)
- chromatin (1)
- chromosome 18 (1)
- chromosome 9 (1)
- chromosomes (1)
- chronic IBD model (1)
- chronic lymphocytic leukemia (1)
- chronische B-Zell Leukaemie (1)
- chronophin (1)
- classical Hodgkin lymphoma (1)
- cleavage (1)
- clonal evolution (1)
- clonality (1)
- clostridium botulinum (1)
- coactivator OBF-1 (1)
- coated vesicles (1)
- cofilin (1)
- colorectal carcinoma (1)
- combined immunodeficiency (1)
- combined therapy (1)
- complement system (1)
- complex (1)
- confocal Raman imaging (1)
- consensus DNA (1)
- cross-priming (1)
- cross-reaction (1)
- cutaneous T-cell-lymphoma (1)
- cycle (1)
- cyclophsophamide (1)
- cyclosporine A (1)
- cytokeratin (1)
- cytotoxicity (1)
- damage (1)
- damage responses (1)
- deformation (1)
- deletions (1)
- diagnosis (1)
- diagnostics (1)
- diffuse large B-Cell lymphoma (1)
- diffuse large B‐cell lymphoma (1)
- disease (1)
- distinct (1)
- down regulation (1)
- drug abuse (1)
- drug resistance (1)
- drug therapy (1)
- eGFP (1)
- early (1)
- early breast cancer (1)
- early diagnosis (1)
- echocardiography (1)
- ectopic lymphoid follicle (1)
- effector Treg (eTreg) (1)
- egfr (1)
- ejection fraction (1)
- embryonic lethality (1)
- encephalitis (1)
- encephalitis lethargica (1)
- endothelium (1)
- enhancer (1)
- enteropathy-type (1)
- ependyoma (1)
- ephitelial cells (1)
- epigenetics (1)
- epithelial markers (1)
- epithelium (1)
- extracorporeal membrane oxygenation (1)
- extrafollicular activation (1)
- extramedullary disease (1)
- features (1)
- ferroptosis (1)
- fetaler Acetylcholinrezeptor (1)
- fibroblast activation protein (1)
- fixation (1)
- fluorenscence (1)
- fluorescence in situ hybridisation (1)
- fluorescent-in -situ-hybridization (1)
- foetal typ acetylcholine receptor (1)
- follicular T helper cells (1)
- follicular lymphoma reactive germinal centers (1)
- follicular regulatory T cell (1)
- follikuläre Lymphome erhaltene reaktive Keimzentren (1)
- follikuläre regulatorische T-Zelle (1)
- follikulärer (1)
- forecasting (1)
- formalin (1)
- formalin-fixed (1)
- formalin-fixiert (1)
- functional characterization (1)
- fungal infection (1)
- gRNA-only (1)
- gastric bypass (1)
- gastrointestinal infections (1)
- gefitinib (1)
- genetic loci (1)
- genetics (1)
- genomic aberrations (1)
- germinal center formation (1)
- germline mutation (1)
- gesolin function (1)
- glioblastoma multiforme (GBM) (1)
- glucocorticoid excess (1)
- glutaminase inhibition (1)
- goldfish optic nerve (1)
- group 3 (1)
- growth (1)
- growth pattern (1)
- growth patterns (1)
- growth-associated protein (1)
- großzellige (1)
- gut–liver axis (1)
- head and neck (1)
- head and neck cancer (1)
- heart (1)
- heart failure (1)
- heatshockprotein (1)
- helicobacter (1)
- helicobacter pylori (1)
- helper T cells (1)
- helper T-cells (1)
- hematopoiesis (1)
- hematopoietic stem cells (1)
- hemophagocytosis (1)
- hepcidin (1)
- high numbers (1)
- high-dose chemotherapy (1)
- high-resolution analysis (1)
- high-risk Prostate Cancer (1)
- high‐grade B‐cell lymphoma (1)
- hippocampal stem cells (1)
- histopathology (1)
- hnRNP K (1)
- hormones (1)
- human (1)
- human antibodies (1)
- human brain (1)
- human cerebral endothelial cells (1)
- human genome (1)
- human monoclonal antibodies (1)
- human monoclonal antibody LM-1 (1)
- human monoclonal antibody PAM-1 (1)
- humane Antikörper (1)
- humane monoklonale Antikörper (1)
- humaner monoklonaler Antikörper LM-1 (1)
- humaner monoklonaler Antikörper PAM-1 (1)
- humanized hemato-lymphoid mice (1)
- humanized mice (1)
- hybridization (1)
- hyper-IgM syndrome type 2 (HIGM2) (1)
- hypercortisolism (1)
- hypermutation (1)
- iiron transporter (1)
- immune cells (1)
- immune check inhibitor (1)
- immune checkpoint blockade (1)
- immune checkpoint inhibitor (ICI) (1)
- immune evasion (1)
- immune infiltration (1)
- immune system (1)
- immunhistochemical analysis of DLBCL (1)
- immunhistochemisch (1)
- immunhistochemische Analyse von DLBCL (1)
- immunity (1)
- immunocytochemistry (1)
- immunofuorescence double staining (1)
- immunoglobulin promoters (1)
- immunoglobuline (1)
- immunohistochemisty (1)
- immunohistological expression analysis (1)
- immunology and microbiology section (1)
- immunophenotype (1)
- immunotherapeutics (1)
- in silico analysis (1)
- in-situ-Hybridisierung (1)
- in-situ-hybridization (1)
- in-vitro (1)
- in-vivo (1)
- independent predictor (1)
- induction (1)
- induction of apoptosis (1)
- inflammation-induced tissue demage (1)
- innate Immunität (1)
- innate antibody (1)
- integrated stress response (1)
- integrin (1)
- interaction (1)
- interleukin-8 (1)
- interleukins (1)
- intestine (1)
- intracranial bleeding (1)
- intraosseous (1)
- intravascular large B‐cell lymphoma (1)
- invasion (1)
- involution (1)
- involvement (1)
- iron in parkinsonism (1)
- iron model (1)
- iron pathology (1)
- isoforms (1)
- karyotype (1)
- kidney cancer (1)
- kinase (1)
- kinases (1)
- kinetic mechanism (1)
- knock down (1)
- knock out mice (1)
- kolorektales Karzinom (1)
- komparative genomische Hybridisierung (1)
- kras (1)
- kras-Mutation (1)
- large cell transformation (1)
- latency type (1)
- lck (1)
- lesions (1)
- leukemia (1)
- lichen planus (1)
- lineage (1)
- lineage differentiation (1)
- lipid droplets (1)
- lipids (1)
- lipoblastoma (1)
- lipoid pneumonitis (1)
- lipotoxicity (1)
- liquid biopsy (1)
- liraglutide (1)
- livin (1)
- lung fibrosis (1)
- lymph node (1)
- lymph node stromal cells (1)
- lymph node transplantation (1)
- lymphatische Tumoren (1)
- lymphocyte (1)
- lymphocyte activation (1)
- lymphocyte differentiation (1)
- lymphocytes (1)
- lymphohistiocytosis (1)
- lymphoid aggregate (1)
- lymphoid hyperplasia (1)
- lymphoid-tissue (1)
- lymphoid-tissue lymphomas (1)
- lymphomas (1)
- mRNA expression (1)
- mTOR (1)
- major histocompatibility complex (1)
- malignancies (1)
- malt lymphoma (1)
- mammalian cells (1)
- mandible (1)
- mantel cell lymphoma (1)
- marcophages (1)
- marginal zone-B-cell-Lymphoma (1)
- marrow transplantation (1)
- mass cytometry (1)
- mast cells (1)
- mastocytosis (1)
- measles virus (1)
- mediastinum (1)
- medical research (1)
- medicine (1)
- membrane topology (1)
- membrane translocation (1)
- memory B cells (1)
- meningeal inflammation (1)
- meningioma (1)
- mesenchymal markers (1)
- mesenteric lymph node (1)
- mesentery (1)
- messenger-RNA transport (1)
- metabolism (1)
- metagenomics (1)
- metastasis-associated in colon cancer 1 (MACC1) (1)
- methylation (1)
- miR-126 (1)
- miR-21 (1)
- microRNA-221 (1)
- microglia (1)
- microsatellite analysis (1)
- microsatellites (1)
- microvessel permeability (1)
- mikrobielle Diversität (1)
- mild hypothermia (1)
- mitochondriale DNA (1)
- mitochondriale DNA-Deletionen (1)
- mitosis (1)
- mitotane (1)
- mitotic genes (1)
- molecular marker (1)
- molecular subtypes (1)
- monoklonale Antikörper (1)
- monoklonaler Antikörper (1)
- morphometry (1)
- mouse model (1)
- mtDNA (1)
- mucosa-associated lymphatic tissue (1)
- mucosal ulcers (1)
- multifocal growth (1)
- multigene-array (1)
- multilobulierte centroblastische Lymphome (1)
- multiple Sclerosis immunomodulation Natalizumab (1)
- multiple sclerosis (1)
- multivariate Prognoseanalyse (1)
- multivariate data analysis (1)
- multi‐organ disease (1)
- murine homolog (1)
- mutant p53 (1)
- mutational targeting (1)
- myasthenia (1)
- mycosis fungoides (1)
- naive T-cell gene editing (1)
- natural IgG antibody (1)
- natural IgM antibodies (1)
- natural antibodies (1)
- natürliche IgM-Antikörper (1)
- natürlicher IgG-Antikörper (1)
- negative selection (1)
- nephroblastoma (1)
- nervous system (1)
- network (1)
- neurodegeneration (1)
- neurodegenerative disease (1)
- neuroendocrine tumor (1)
- neurogene Schädigung (1)
- neuromelanin (1)
- neuromucular disorders (1)
- neurooncology (1)
- neuropathology (1)
- neuroscience (1)
- neurotoxicity (1)
- neurovascular unit (1)
- neutral loss (1)
- next generation sequencing (1)
- niche (1)
- nicotinic acetylcholine receptor (1)
- nodal (1)
- nodal peripheral T-cell lymphoma (1)
- nodales peripheres T-Zell-Lymphom (1)
- nodular lymphcyte (1)
- non-GCB-Subtyp (1)
- non-GCB-like (1)
- non-Hodgkin lymphoma (1)
- non-hodgkin lymphoma (1)
- non-hodgkin-lymphoma (1)
- non-small cell lung cancer (1)
- noncoding RNAs (1)
- normal adrenal glands (1)
- notch signaling (1)
- nuclear DNA content (1)
- nukleare DNA-Inhalt (1)
- nur77 (1)
- obinutuzumab (1)
- octreotide (1)
- olfactory bulb (1)
- oncogene (1)
- organotypic hippocampal slice cultures (OHSC) (1)
- orthotopic xenograft (1)
- osteoarthritis (1)
- osteonecrosis of jaw (1)
- outcomes research (1)
- outreach (1)
- oxidativer Stress (1)
- p300 (1)
- p53 expression (1)
- p53-dependent apoptosis (1)
- p53-inducible regulator (1)
- pFADD (1)
- pan-RCC (1)
- panel sequencing (1)
- panel-sequencing (1)
- panniculitis (1)
- paraffin-eingebettet (1)
- paraffin-embedded (1)
- parathyroid carcinoma (1)
- parkinson’s disease (1)
- pathogenesis (1)
- pathohistology (1)
- pathology (1)
- pathway (1)
- patient access (1)
- patient survival (1)
- pediatric (1)
- pediatric lymphoma (1)
- pembrolizumab (1)
- peptide receptor radionuclide therapy (1)
- peptide receptor radionuclide therapy (PRRT) (1)
- peptide tyrosine tyrosine (PYY) (1)
- peptide tyrosine tyrosine 3-36 (PYY\(_{3-36}\)) (1)
- peripheral T-cell (1)
- peripheral T-cell lymphoma (1)
- periphere T-Zell-Lymphome (1)
- phosphatase 2A (1)
- phospholipase A(2) (1)
- plasmablasts (1)
- pleural mesothelioma (1)
- polyadenylation (1)
- post-mortem heart recovery (1)
- postencephalitic parkinsonism (1)
- posttranslational modification (1)
- posttranslationale Modifikation (1)
- potentiell therapeutisch relevante Proteine (1)
- precancerous lesions (1)
- precision oncology (1)
- prediction (1)
- primary bone marrow presentation (1)
- primary cell culture (1)
- primary cutaneous follicular B-cell lymphoma (1)
- primary cutaneous lymphoma (1)
- primary cutaneous marginal zone lymphomas (1)
- pro-inflammatory cytokines (1)
- prognostic factor (1)
- prognostic factors (1)
- prognostic marker (1)
- prognostic value (1)
- progressive multiple sclerosis (1)
- proliferation (1)
- prophylaxis (1)
- prostate cancer (1)
- prostate carcinoma (1)
- prostate gland DNA – database (1)
- prostate gland cancer (1)
- protein and mRNA expression (1)
- proteins (1)
- pseudocarcinomatous hyperplasia (1)
- pseudolymphoma (1)
- psoas muscle (1)
- psoriasis (1)
- radiation (1)
- radiation-induced migration (1)
- rag (1)
- raman spectroscopy (1)
- rare SNP (1)
- real world data (1)
- receptor expression (1)
- recurrence-free survival (1)
- refractory/relapsed lymphoma (1)
- regional development (1)
- regulatory T-cells (1)
- renal cancer (1)
- renal cell carcinoma (1)
- repeated surgery (1)
- resistance (1)
- resistance to apoptosis (1)
- restoration (1)
- retroperitoneal tumor (1)
- retroperitoneum (1)
- retroviral gene transfer (1)
- retroviral vector system (1)
- retrovirales Vektorsystem (1)
- reverse transcriptase-polymerase chain reaction (1)
- rhesus monkeys (1)
- rheumatoid arthritis (1)
- rheumatoiden Arthritis (1)
- ribosome (1)
- ribosyltransferase (1)
- risk (1)
- roquin (1)
- rotator-cuff injury (1)
- sFas (1)
- salivary gland (1)
- salivary gland neoplasia (1)
- salivary gland tumor (1)
- salivary gland tumors (1)
- salivary glands (1)
- sarcoma (1)
- scoring system (1)
- selective vulnerability (1)
- selektive Vulnerabilität (1)
- seminoma (1)
- senescence (1)
- senile Lymphoproliferation (1)
- serum (1)
- shaken baby syndrome (1)
- siv (1)
- slice culture (1)
- somatic hypermutation (1)
- somatic mutations (1)
- somatostatine (1)
- spinal-cord-injury (1)
- spleen (1)
- splice variant (1)
- sporadische Alzheimer-Demenz (1)
- squamous tumors (1)
- staphylococcal abscess (1)
- stem cell transplantation (1)
- stem-cells (1)
- stemness (1)
- stomach carcinoma (1)
- storage solution (1)
- stratification (1)
- subventricular zone (1)
- suppression (1)
- suppressor (1)
- surgery (1)
- surgical and invasive medical procedures (1)
- surgical treatment (1)
- systemic sclerosis (1)
- t cells (1)
- t(11;18)(q21;q21) (1)
- t(14;18)-negative follicular lymphoma (1)
- t(14;18)-negative follikuläre Lymphome (1)
- t-SNE (1)
- t-cell maturation (1)
- t-cell-lymphoma (1)
- target (1)
- target validation (1)
- targeted (1)
- targeted combination therapy (1)
- targeted sequencing (1)
- targeted therapies (1)
- tauopathy (1)
- telepathology (1)
- tetraspanin (1)
- tetraspanin protein (1)
- theranostics (1)
- therapeutic target (1)
- therapy response (1)
- thiol starvation (1)
- thymic epithelial tumor (1)
- thymitis (1)
- thymocytes (1)
- thymopoiesis (1)
- tissue preparation (1)
- tissuemicroarray (1)
- tofacitinib (1)
- transcript (1)
- transcription factor FOXP1 (1)
- transcriptional repression (1)
- transcriptome (1)
- transcriptomic analysis (1)
- transformation (1)
- translocation t(11;14)(q13;q32) (1)
- translocation t(11;18) (1)
- transplantation (1)
- trastuzumab (1)
- trastuzumab deruxtecan (1)
- treatment regimens (1)
- treg cells (1)
- triple-negative breast cancer (1)
- trisomy (1)
- tumor (1)
- tumor cell migration (1)
- tumor heterogeneity (1)
- tumor progression (1)
- tumor slice cultures (1)
- tumor specific antibody (1)
- tumor spheroids (1)
- tumor vaccination (1)
- tumor-vessel wall-interface model (1)
- tumorigenesis (1)
- tumormicroenvironment (1)
- tumors (1)
- tumorspecific (1)
- tumorspezifisch (1)
- tumorspezifische Antikörper (1)
- tumour heterogeneity (1)
- typ 1 muscle fibres (1)
- tyrosine kinase inhibitor (TKI) (1)
- uPA (1)
- ubiquitin (1)
- unspezifische Lymphadenitis (1)
- unsupervised clustering (1)
- up regulation (1)
- urinary bladder cancer (1)
- urothelial carcinoma (1)
- vascular wall stem and progenitor cells (1)
- vascularization model (1)
- vasculogenesis (1)
- vemurafenib (1)
- venetoclax (1)
- virus–iron interaction (1)
- visual clustering (1)
- vitamin D receptor (1)
- vitamin k deficiency bleeding (1)
- vitamin metabolism (1)
- von Economo (1)
- whole-exome sequencing (1)
- xxx (1)
- Östrogene (1)
- Überleben (1)
- Überlebenszeit (1)
- ɑ-Synuclein and iron (1)
- α-synuclein-specific T cells (1)
Institute
- Pathologisches Institut (323) (remove)
Schriftenreihe
Sonstige beteiligte Institutionen
- Center for Interdisciplinary Clinical Research, Würzburg University, Würzburg, Germany (1)
- Department of Paediatric Radiology, Institute of Diagnostic and Interventional Radiology, Josef-Schneider-Straße 2, Wuerzburg 97080, Germany (1)
- IZKF Nachwuchsgruppe Geweberegeneration für muskuloskelettale Erkrankungen (1)
- Lehrstuhl für Regeneration Muskuloskelettaler Gewebe (1)
- Muskuloskelettales Centrum Würzburg (MCW) (1)
Delayed and limited administration of the JAKinib tofacitinib mitigates chronic DSS-induced colitis
(2023)
In inflammatory bowel disease, dysregulated T cells express pro-inflammatory cytokines. Using a chronic azoxymethane (AOM)/dextran sulfate sodium (DSS)-induced colitis model resembling ulcerative colitis, we evaluated whether and when treatment with the Janus kinase (JAK) inhibitor tofacitinib could be curative. Comparing the treatment with two and three cycles of tofacitinib medication in drinking water – intermittently with DSS induction – revealed that two cycles were not only sufficient but also superior over the 3-x regimen. The two cycles of the 2-x protocol paralleled the second and third cycles of the longer protocol. T cells were less able to express interferon gamma (IFN-γ) and the serum levels of IFN-γ, interleukin (IL)-2, IL-6, IL-17, and tumor necrosis factor (TNF) were significantly reduced in sera, while those of IL-10 and IL-22 increased under the 2-x protocol. Likewise, the frequency and effector phenotype of regulatory T cells (Tregs) increased. This was accompanied by normal weight gain, controlled clinical scores, and restored stool consistency. The general and histologic appearance of the colons revealed healing and tissue intactness. Importantly, two phases of tofacitinib medication completely prevented AOM-incited pseudopolyps and the hyper-proliferation of epithelia, which was in contrast to the 3-x regimen. This implies that the initial IBD-induced cytokine expression is not necessarily harmful as long as inflammatory signaling can later be suppressed and that time-restricted treatment allows for anti-inflammatory and tissue-healing cytokine activities.
Next-generation humanized NSG-SGM3 mice are highly susceptible to Staphylococcus aureus infection
(2023)
Humanized hemato-lymphoid system mice, or humanized mice, emerged in recent years as a promising model to study the course of infection of human-adapted or human-specific pathogens. Though Staphylococcus aureus infects and colonizes a variety of species, it has nonetheless become one of the most successful human pathogens of our time with a wide armory of human-adapted virulence factors. Humanized mice showed increased vulnerability to S. aureus compared to wild type mice in a variety of clinically relevant disease models. Most of these studies employed humanized NSG (NOD-scid IL2Rgnull) mice which are widely used in the scientific community, but show poor human myeloid cell reconstitution. Since this immune cell compartment plays a decisive role in the defense of the human immune system against S. aureus, we asked whether next-generation humanized mice, like NSG-SGM3 (NOD-scid IL2Rgnull-3/GM/SF) with improved myeloid reconstitution, would prove to be more resistant to infection. To our surprise, we found the contrary when we infected humanized NSG-SGM3 (huSGM3) mice with S. aureus: although they had stronger human immune cell engraftment than humanized NSG mice, particularly in the myeloid compartment, they displayed even more pronounced vulnerability to S. aureus infection. HuSGM3 mice had overall higher numbers of human T cells, B cells, neutrophils and monocytes in the blood and the spleen. This was accompanied by elevated levels of pro-inflammatory human cytokines in the blood of huSGM3 mice. We further identified that the impaired survival of huSGM3 mice was not linked to higher bacterial burden nor to differences in the murine immune cell repertoire. Conversely, we could demonstrate a correlation of the rate of humanization and the severity of infection. Collectively, this study suggests a detrimental effect of the human immune system in humanized mice upon encounter with S. aureus which might help to guide future therapy approaches and analysis of virulence mechanisms.
Multiorgan recovery in a cadaver body using mild hypothermic ECMO treatment in a murine model
(2023)
Background
Transplant candidates on the waiting list are increasingly challenged by the lack of organs. Most of the organs can only be kept viable within very limited timeframes (e.g., mere 4–6 h for heart and lungs exposed to refrigeration temperatures ex vivo). Donation after circulatory death (DCD) using extracorporeal membrane oxygenation (ECMO) can significantly enlarge the donor pool, organ yield per donor, and shelf life. Nevertheless, clinical attempts to recover organs for transplantation after uncontrolled DCD are extremely complex and hardly reproducible. Therefore, as a preliminary strategy to fulfill this task, experimental protocols using feasible animal models are highly warranted. The primary aim of the study was to develop a model of ECMO-based cadaver organ recovery in mice. Our model mimics uncontrolled organ donation after an “out-of-hospital” sudden unexpected death with subsequent “in-hospital” cadaver management post-mortem. The secondary aim was to assess blood gas parameters, cardiac activity as well as overall organ state. The study protocol included post-mortem heparin–streptokinase administration 10 min after confirmed death induced by cervical dislocation under full anesthesia. After cannulation, veno-arterial ECMO (V–A ECMO) was started 1 h after death and continued for 2 h under mild hypothermic conditions followed by organ harvest. Pressure- and flow-controlled oxygenated blood-based reperfusion of a cadaver body was accompanied by blood gas analysis (BGA), electrocardiography, and histological evaluation of ischemia–reperfusion injury. For the first time, we designed and implemented, a not yet reported, miniaturized murine hemodialysis circuit for the treatment of severe hyperkalemia and metabolic acidosis post-mortem.
Results
BGA parameters confirmed profound ischemia typical for cadavers and incompatible with normal physiology, including extremely low blood pH, profound negative base excess, and enormously high levels of lactate. Two hours after ECMO implantation, blood pH values of a cadaver body restored from < 6.5 to 7.3 ± 0.05, pCO2 was lowered from > 130 to 41.7 ± 10.5 mmHg, sO2, base excess, and HCO3 were all elevated from below detection thresholds to 99.5 ± 0.6%, − 4 ± 6.2 and 22.0 ± 6.0 mmol/L, respectively (Student T test, p < 0.05). A substantial decrease in hyperlactatemia (from > 20 to 10.5 ± 1.7 mmol/L) and hyperkalemia (from > 9 to 6.9 ± 1.0 mmol/L) was observed when hemodialysis was implemented. On balance, the first signs of regained heart activity appeared on average 10 min after ECMO initiation without cardioplegia or any inotropic and vasopressor support. This was followed by restoration of myocardial contractility with a heart rate of up to 200 beats per minute (bpm) as detected by an electrocardiogram (ECG). Histological examinations revealed no evidence of heart injury 3 h post-mortem, whereas shock-specific morphological changes relevant to acute death and consequent cardiac/circulatory arrest were observed in the lungs, liver, and kidney of both control and ECMO-treated cadaver mice.
Conclusions
Thus, our model represents a promising approach to facilitate studying perspectives of cadaveric multiorgan recovery for transplantation. Moreover, it opens new possibilities for cadaver organ treatment to extend and potentiate donation and, hence, contribute to solving the organ shortage dilemma.
Background
Hematogenous tumor spread of malignant meningiomas occurs very rarely but is associated with very poor prognosis.
Case presentation
We report an unusual case of a patient with a malignant meningioma who developed multiple metastases in bones, lungs and liver after initial complete resection of the primary tumor. After partial hepatic resection, specimens were histologically analyzed, and a complete loss of E-cadherin adhesion molecules was found. No oncogenic target mutations were found. The patient received a combination of conventional radiotherapy and peptide receptor radionuclide therapy (PRRT). Due to aggressive tumor behavior and rapid spread of metastases, the patient deceased after initiation of treatment.
Conclusions
E-cadherin downregulation is associated with a higher probability of tumor invasion and distant metastasis formation in malignant meningioma. Up to now, the efficacy of systemic therapy, including PRRT, is very limited in malignant meningioma patients.
The cystine/glutamate antiporter xCT is an important source of cysteine for cancer cells. Once taken up, cystine is reduced to cysteine and serves as a building block for the synthesis of glutathione, which efficiently protects cells from oxidative damage and prevents ferroptosis. As melanomas are particularly exposed to several sources of oxidative stress, we investigated the biological role of cysteine and glutathione supply by xCT in melanoma. xCT activity was abolished by genetic depletion in the Tyr::CreER; Braf\(^{CA}\); Pten\(^{lox/+}\) melanoma model and by acute cystine withdrawal in melanoma cell lines. Both interventions profoundly impacted melanoma glutathione levels, but they were surprisingly well tolerated by murine melanomas in vivo and by most human melanoma cell lines in vitro. RNA sequencing of human melanoma cells revealed a strong adaptive upregulation of NRF2 and ATF4 pathways, which orchestrated the compensatory upregulation of genes involved in antioxidant defence and de novo cysteine biosynthesis. In addition, the joint activation of ATF4 and NRF2 triggered a phenotypic switch characterized by a reduction of differentiation genes and induction of pro-invasive features, which was also observed after erastin treatment or the inhibition of glutathione synthesis. NRF2 alone was capable of inducing the phenotypic switch in a transient manner. Together, our data show that cystine or glutathione levels regulate the phenotypic plasticity of melanoma cells by elevating ATF4 and NRF2.
Salivary gland tumors (SGTs) are a relevant, highly diverse subgroup of head and neck tumors whose entity determination can be difficult. Confocal Raman imaging in combination with multivariate data analysis may possibly support their correct classification. For the analysis of the translational potential of Raman imaging in SGT determination, a multi-stage evaluation process is necessary. By measuring a sample set of Warthin tumor, pleomorphic adenoma and non-tumor salivary gland tissue, Raman data were obtained and a thorough Raman band analysis was performed. This evaluation revealed highly overlapping Raman patterns with only minor spectral differences. Consequently, a principal component analysis (PCA) was calculated and further combined with a discriminant analysis (DA) to enable the best possible distinction. The PCA-DA model was characterized by accuracy, sensitivity, selectivity and precision values above 90% and validated by predicting model-unknown Raman spectra, of which 93% were classified correctly. Thus, we state our PCA-DA to be suitable for parotid tumor and non-salivary salivary gland tissue discrimination and prediction. For evaluation of the translational potential, further validation steps are necessary.
Highlights
• The integrated stress response leads to a general ATF4-dependent activation of NRF2
• ATF4 causes a CHAC1-dependent GSH depletion, resulting in NRF2 stabilization
• An elevation of NRF2 transcript levels fosters this effect
• NRF2 supports the ISR/ATF4 pathway by improving cystine and antioxidant supply
Summary
The redox regulator NRF2 becomes activated upon oxidative and electrophilic stress and orchestrates a response program associated with redox regulation, metabolism, tumor therapy resistance, and immune suppression. Here, we describe an unrecognized link between the integrated stress response (ISR) and NRF2 mediated by the ISR effector ATF4. The ISR is commonly activated after starvation or ER stress and plays a central role in tissue homeostasis and cancer plasticity. ATF4 increases NRF2 transcription and induces the glutathione-degrading enzyme CHAC1, which we now show to be critically important for maintaining NRF2 activation. In-depth analyses reveal that NRF2 supports ATF4-induced cells by increasing cystine uptake via the glutamate-cystine antiporter xCT. In addition, NRF2 upregulates genes mediating thioredoxin usage and regeneration, thus balancing the glutathione decrease. In conclusion, we demonstrate that the NRF2 response serves as second layer of the ISR, an observation highly relevant for the understanding of cellular resilience in health and disease.
Diagnosing any of the more than 30 types of T-cell lymphomas is considered a challenging task for many pathologists and currently requires morphological expertise as well as the integration of clinical data, immunophenotype, flow cytometry and clonality analyses. Even considering all available information, some margin of doubt might remain using the current diagnostic procedures. In recent times, the genetic landscape of most T-cell lymphomas has been elucidated, showing a number of diagnostically relevant mutations. In addition, recent data indicate that some of these genetic alterations might bear prognostic and predictive value. Extensive genetic analyses, such as whole exome or large panel sequencing are still expensive and time consuming, therefore limiting their application in routine diagnostic. We therefore devoted our effort to develop a lean approach for genetic analysis of T-cell lymphomas, focusing on maximum efficiency rather than exhaustively covering all possible targets. Here we report the results generated with our small amplicon-based panel that could be used routinely on paraffin-embedded and even decalcified samples, on a single sample basis in parallel with other NGS-panels used in our routine diagnostic lab, in a relatively short time and with limited costs. We tested 128 available samples from two German reference centers as part of our routine work up (among which 116 T-cell lymphomas), which is the largest routine diagnostic series reported to date. Our results showed that this assay had a very high rate of technical success (97%) and could detect mutations in the majority (79%) of tested T-cell lymphoma samples.
Idiopathic Parkinson’s disease (PD) is characterized by a progredient degeneration of the brain, starting at deep subcortical areas such as the dorsal motor nucleus of the glossopharyngeal and vagal nerves (DM) (stage 1), followed by the coeruleus–subcoeruleus complex; (stage 2), the substantia nigra (SN) (stage 3), the anteromedial temporal mesocortex (MC) (stage 4), high-order sensory association areas and prefrontal fields (HC) (stage 5) and finally first-order sensory association areas, premotor areas, as well as primary sensory and motor field (FC) (stage 6). Autoimmunity might play a role in PD pathogenesis. Here we analyzed whether anti-brain autoantibodies differentially recognize different human brain areas and identified autoantigens that correlate with the above-described dissemination of PD pathology in the brain. Brain tissue was obtained from deceased individuals with no history of neurological or psychiatric disease and no neuropathological abnormalities. Tissue homogenates from different brain regions (DM, SN, MC, HC, FC) were subjected to SDS-PAGE and Western blot. Blots were incubated with plasma samples from 30 PD patients and 30 control subjects and stained with anti-IgG antibodies to detect anti-brain autoantibodies. Signals were quantified. Prominent autoantigens were identified by 2D-gel-coupled mass spectrometry sequencing. Anti-brain autoantibodies are frequent and occur both in healthy controls and individuals with PD. Glial fibrillary acidic protein (GFAP) was identified as a prominent autoantigen recognized in all plasma samples. GFAP immunoreactivity was highest in DM areas and lowest in FC areas with no significant differences in anti-GFAP autoantibody titers between healthy controls and individuals with PD. The anti-GFAP autoimmunoreactivity of different brain areas correlates with the dissemination of histopathological neurodegeneration in PD. We hypothesize that GFAP autoantibodies are physiological but might be involved as a cofactor in PD pathogenesis secondary to a leakage of the blood–brain barrier.
Purpose
While [\(^{18}\)F]-fluorodeoxyglucose ([\(^{18}\)F]FDG) is the standard for positron emission tomography/computed tomography (PET/CT) imaging of oral squamous cell carcinoma (OSCC), diagnostic specificity is hampered by uptake in inflammatory cells such as neutrophils or macrophages. Recently, molecular imaging probes targeting fibroblast activation protein α (FAP), which is overexpressed in a variety of cancer-associated fibroblasts, have become available and might constitute a feasible alternative to FDG PET/CT.
Methods
Ten consecutive, treatment-naïve patients (8 males, 2 females; mean age, 62 ± 9 years) with biopsy-proven OSCC underwent both whole-body [\(^{18}\)F]FDG and [\(^{68}\)Ga]FAPI-04 (FAP-directed) PET/CT for primary staging prior to tumor resection and cervical lymph node dissection. Detection of the primary tumor, as well as the presence and number of lymph node and distant metastases was analysed. Intensity of tracer accumulation was assessed by means of maximum (SUV\(_{max}\)) and peak (SUV\(_{peak}\) standardized uptake values. Histological work-up including immunohistochemical staining for FAP served as standard of reference.
Results
[\(^{18}\)F]FDG and FAP-directed PET/CT detected all primary tumors with a SUVmax of 25.5 ± 13.2 (FDG) and 20.5 ± 6.4 (FAP-directed) and a SUVpeak of 16.1 ± 10.3 ([\(^{18}\)F]FDG) and 13.8 ± 3.9 (FAP-directed), respectively. Regarding cervical lymph node metastases, FAP-directed PET/CT demonstrated comparable sensitivity (81.3% vs. 87.5%; P = 0.32) and specificity (93.3% vs. 81.3%; P = 0.16) to [\(^{18}\)F]FDG PET/CT. FAP expression on the cell surface of cancer-associated fibroblasts in both primary lesions as well as lymph nodes metastases was confirmed in all samples.
Conclusion
FAP-directed PET/CT in OSCC seems feasible. Future research to investigate its potential to improve patient staging is highly warranted.
The subclassification of diffuse large B-cell lymphoma (DLBCL) into germinal center B-cell-like (GCB) and activated B-cell-like (ABC) subtypes has become mandatory in the 2017 update of the WHO classification of lymphoid neoplasms and will continue to be used in the WHO 5\(^{th}\) edition. The RNA-based Lymph2Cx assay has been validated as a reliable surrogate of high-throughput gene expression profiling assays for distinguishing between GCB and ABC DLBCL and provides reliable results from formalin-fixed, paraffin-embedded (FFPE) material. This test has been previously used in clinical trials, but experience from real-world routine application is rare. We routinely applied the Lymph2Cx assay to day-to-day diagnostics on a series of 147 aggressive B-cell lymphoma cases and correlated our results with the immunohistochemical subclassification using the Hans algorithm and fluorescence in situ hybridization findings using break-apart probes for MYC, BCL2, and BCL6. The routine use of the Lymph2Cx assay had a high technical success rate (94.6%) with a low rate of failure due to poor material and/or RNA quality. The Lymph2Cx assay was discordant with the Hans algorithm in 18% (23 of 128 cases). Discordant cases were mainly classified as GCB by the Hans algorithm and as ABC by Lymph2Cx (n = 11, 8.6%). Only 5 cases (3.9%) were classified as non-GCB by the Hans algorithm and as GCB by Lymph2Cx. Additionally, 5.5% of cases (n = 7) were left unclassified by Lymph2Cx, whereas they were defined as GCB (n = 4) or non-GCB (n = 3) by the Hans algorithm. Our data support the routine applicability of the Lymph2Cx assay.
Background
Panniculitis-like T-cell lymphoma is an uncommon type of non-Hodgkin lymphoma, occurring usually in the form of nodules within the subcutaneous fat tissue of the extremities or trunk. In the literature, subcutaneous panniculitis-like T-cell lymphoma (SPTCL) is described as a distinct type of T-cell lymphoma with a variable clinical behavior, depending on molecular phenotype of T-cell receptor (TCR) and on the presence or absence of hemophagocytic syndrome.
Case presentation
We present a bioptic and autoptic case of a 65-years old Caucasian man with panniculitic T-cell lymphoma with morphological and immunohistochemical features of SPTCL, limited to the retroperitoneal and mesenteric mass, i.e. without any cutaneous involvement, and associated with severe hemophagocytic lymphohistiocytosis.
Conclusion
A panniculitic T-cell lymphoma with morphological and molecular features of SPTCL, which is limited to mesentery, i.e. does not involve subcutaneous fat, seems to be exceedingly rare.
Routine coronal paraffin-sections through the dorsal frontal and parieto-occipital cortex of a total of sixty cases with divergent causes of death were immunohistochemically (IHC) stained with an antibody against TMEM119. Samples of cerebrospinal fluid (CSF) of the same cases were collected by suboccipital needle-puncture, subjected to centrifugation and processed as cytospin preparations stained with TMEM119. Both, cytospin preparations and sections were subjected to computer-assisted density measurements. The density of microglial TMEM119-positive cortical profiles correlated with that of cytospin results and with the density of TMEM119-positive microglial profiles in the medullary layer. There was no statistically significant correlation between the density of medullary TMEM119-positive profiles and the cytospin data. Cortical microglial cells were primarily encountered in supragranular layers I, II, and IIIa and in infragranular layers V and VI, the region of U-fibers and in circumscribed foci or spread in a diffuse manner and high density over the white matter. We have evidence that cortical microglia directly migrate into CSF without using the glympathic pathway. Microglia in the medullary layer shows a strong affinity to the adventitia of deep vessels in the myelin layer. Selected rapidly fatal cases including myocardial infarcts and drowning let us conclude that microglia in cortex and myelin layer can react rapidly and its reaction and migration is subject to pre-existing external and internal factors. Cytospin preparations proved to be a simple tool to analyze and assess complex changes in the CNS after rapid fatal damage. There is no statistically significant correlation between cytospin and postmortem interval. Therefore, the quantitative analyses of postmortem cytospins obviously reflect the neuropathology of the complete central nervous system. Cytospins provide forensic pathologists a rather simple and easy to perform method for the global assessment of CNS affliction.
Hyper-IgM syndrome type 2 (HIGM2) is a B cell intrinsic primary immunodeficiency caused by mutations in AICDA encoding activation-induced cytidine deaminase (AID) which impair immunoglobulin class switch recombination (CSR) and somatic hypermutation (SHM). Whereas autosomal-recessive AID-deficiency (AR-AID) affects both CSR and SHM, the autosomal-dominant form (AD-AID) due to C-terminal heterozygous variants completely abolishes CSR but only partially affects SHM. AR-AID patients display enhanced germinal center (GC) reactions and autoimmune manifestations, which are not present in AD-AID, suggesting that SHM but not CSR regulates GC reactions and peripheral B cell tolerance. Herein, we describe two siblings with HIGM2 due to a novel homozygous AICDA mutation (c.428-1G > T) which disrupts the splice acceptor site of exon 4 and results in the sole expression of a truncated AID variant that lacks 10 highly conserved amino acids encoded by exon 4 (AID-ΔE4a). AID-ΔE4a patients suffered from defective CSR and enhanced GC reactions and were therefore indistinguishable from other AR-AID patients. However, the AID-ΔE4a variant only partially affected SHM as observed in AD-AID patients. In addition, AID-ΔE4a but not AD-AID patients revealed impaired targeting of mutational hotspot motives and distorted mutational patterns. Hence, qualitative defects in AID function and altered SHM rather than global decreased SHM activity may account for the disease phenotype in these patients.
Molecular-based subclassifications of breast cancer are important for identifying treatment options and stratifying the prognosis in breast cancer. This study aimed to assess the prognosis relative to disease-free survival (DFS) and overall survival (OS) in patients with triple-negative breast cancer (TNBC) and other subtypes, using a biomarker panel including cytokeratin 5 (CK5), cluster of differentiation 117 (CD117), and epidermal growth factor receptor (EGFR). This cohort–case study included histologically confirmed breast carcinomas as cohort arm. From a total of 894 patients, 572 patients with early breast cancer, sufficient clinical data, and archived tumor tissue were included. Using the immunohistochemical markers CK5, CD117, and EGFR, two subgroups were formed: one with all three biomarkers negative (TBN) and one with at least one of those three biomarkers positive (non-TBN). There were significant differences between the two biomarker subgroups (TBN versus non-TBN) in TNBC for DFS (p = 0.04) and OS (p = 0.02), with higher survival rates (DFS and OS) in the non-TBN subgroup. In this study, we found the non-TBN subgroup of TNBC lesions with at least one positive biomarker of CK5, CD117, and/or EGFR, to be associated with longer DFS and OS.
Due to the wide variety of benign and malignant salivary gland tumors, classification and malignant behavior determination based on histomorphological criteria can be difficult and sometimes impossible. Spectroscopical procedures can acquire molecular biological information without destroying the tissue within the measurement processes. Since several tissue preparation procedures exist, our study investigated the impact of these preparations on the chemical composition of healthy and tumorous salivary gland tissue by Fourier-transform infrared (FTIR) microspectroscopy. Sequential tissue cross-sections were prepared from native, formalin-fixed and formalin-fixed paraffin-embedded (FFPE) tissue and analyzed. The FFPE cross-sections were dewaxed and remeasured. By using principal component analysis (PCA) combined with a discriminant analysis (DA), robust models for the distinction of sample preparations were built individually for each parotid tissue type. As a result, the PCA-DA model evaluation showed a high similarity between native and formalin-fixed tissues based on their chemical composition. Thus, formalin-fixed tissues are highly representative of the native samples and facilitate a transfer from scientific laboratory analysis into the clinical routine due to their robust nature. Furthermore, the dewaxing of the cross-sections entails the loss of molecular information. Our study successfully demonstrated how FTIR microspectroscopy can be used as a powerful tool within existing clinical workflows.
The metastatic suppressor BRMS1 interacts with critical steps of the metastatic cascade in many cancer entities. As gliomas rarely metastasize, BRMS1 has mainly been neglected in glioma research. However, its interaction partners, such as NFκB, VEGF, or MMPs, are old acquaintances in neurooncology. The steps regulated by BRMS1, such as invasion, migration, and apoptosis, are commonly dysregulated in gliomas. Therefore, BRMS1 shows potential as a regulator of glioma behavior. By bioinformatic analysis, in addition to our cohort of 118 specimens, we determined BRMS1 mRNA and protein expression as well as its correlation with the clinical course in astrocytomas IDH mutant, CNS WHO grade 2/3, and glioblastoma IDH wild-type, CNS WHO grade 4. Interestingly, we found BRMS1 protein expression to be significantly decreased in the aforementioned gliomas, while BRMS1 mRNA appeared to be overexpressed throughout. This dysregulation was independent of patients’ characteristics or survival. The protein and mRNA expression differences cannot be finally explained at this stage. However, they suggest a post-transcriptional dysregulation that has been previously described in other cancer entities. Our analyses present the first data on BRMS1 expression in gliomas that can provide a starting point for further investigations.
While glioblastoma (GBM) is still challenging to treat, novel immunotherapeutic approaches have shown promising effects in preclinical settings. However, their clinical breakthrough is hampered by complex interactions of GBM with the tumor microenvironment (TME). Here, we present an analysis of TME composition in a patient-derived organoid model (PDO) as well as in organotypic slice cultures (OSC). To obtain a more realistic model for immunotherapeutic testing, we introduce an enhanced PDO model. We manufactured PDOs and OSCs from fresh tissue of GBM patients and analyzed the TME. Enhanced PDOs (ePDOs) were obtained via co-culture with PBMCs (peripheral blood mononuclear cells) and compared to normal PDOs (nPDOs) and PT (primary tissue). At first, we showed that TME was not sustained in PDOs after a short time of culture. In contrast, TME was largely maintained in OSCs. Unfortunately, OSCs can only be cultured for up to 9 days. Thus, we enhanced the TME in PDOs by co-culturing PDOs and PBMCs from healthy donors. These cellular TME patterns could be preserved until day 21. The ePDO approach could mirror the interaction of GBM, TME and immunotherapeutic agents and may consequently represent a realistic model for individual immunotherapeutic drug testing in the future.
Purpose
Therapeutic options for breast cancer (BC) treatment are constantly evolving. The Human Epidermal Growth Factor 2 (HER2)-low BC entity is a new subgroup, representing about 55% of all BC patients. New antibody–drug conjugates demonstrated promising results for this BC subgroup. Currently, there is limited information about the conversion of HER2 subtypes between primary tumor and recurrent disease.
Methods
This retrospective study included women with BC at the University Medical Centre Wuerzburg from 1998 to 2021. Data were retrieved from patients' records. HER2 evolution from primary diagnosis to the first relapse and the development of secondary metastases was investigated.
Results
In the HR-positive subgroup without HER2 overexpression, HER2-low expression in primary BC was 56.7 vs. 14.6% in the triple-negative subgroup (p < 0.000). In the cohort of the first relapse, HER2-low represented 64.1% of HR-positive vs. 48.2% of the triple-negative cohort (p = 0.03). In patients with secondary metastases, HER2-low was 75.6% vs. 50% in the triple negative subgroup (p = 0.10). The subgroup of HER2-positive breast cancer patients numerically increased in the course of disease; the HER2-negative overall cohort decreased. A loss of HER2 expression from primary BC to the first relapse correlated with a better OS (p = 0.018). No clinicopathological or therapeutic features could be identified as potential risk factors for HER2 conversion.
Conclusion
HER2 expression is rising during the progression of BC disease. In view of upcoming therapeutical options, the re-analysis of newly developed metastasis will become increasingly important.
„Black esophagus“ oder „akute Ösophagusnekrose“ (AÖN) ist eine seltene Erkrankung, die sich makroskopisch durch eine zirkumferente Schwarzverfärbung der Ösophagusmukosa mit abruptem Ende am gastroösophagealen Übergang auszeichnet. Die genaue Pathogenese ist unbekannt; es werden multifaktorielle Einflüsse wie z. B. Säurereflux, Ischämie und verringerte Schutzmechanismen der Mukosa als mögliche Ursachen diskutiert.
Vorgestellt werden 2 Obduktionsfälle, die typische Befunde einer AÖN aufwiesen. Zusätzlich hatten Fall 1 eine Candida-Infektion und Fall 2 eine Appendizitis, sodass eine infektiöse Genese in beiden Fällen eine Rolle gespielt haben könnte.